Relugolix: Novel Drug for ADT in Advanced Prostate Cancer Relugolix: Novel Drug for ADT in Advanced Prostate Cancer
Investigational agent relugolix was non-inferior to leuprolide but also significantly cut the risk of major adverse cardiovascular events.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
More News: Cancer | Cancer & Oncology | Cardiology | Cardiovascular | Heart | Hematology | Prostate Cancer